>>The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study.
Time: Saturday, June 05, 2004, 8:00am-12:00pm
Presenter: Angela M. Davies, MD
Abstract ID: 7106
Poster Number: T5
Session: Lung Cancer
Saturday, June 05, 2004, 8:00am-12:00pm
Location: Hall A (right half) <<
>>Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results.
Time: Saturday, June 05, 2004, 8:00am-12:00pm
Presenter: Michael P. Fanucchi, MD
Abstract ID: 7107
Poster Number: T6
Session: Lung Cancer
Saturday, June 05, 2004, 8:00am-12:00pm
Location: Hall A (right half) <<
>>Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts.
Time: Saturday, June 05, 2004, 8:00am-12:00pm
Presenter: Paul H. Gumerlock, PhD
Abstract ID: 7144
Poster Number: W10
Session: Lung Cancer
Saturday, June 05, 2004, 8:00am-12:00pm
Location: Hall A (right half)<<
>>Effects of bortezomib (PS-341) on NF-êB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial.
Time: Saturday, June 05, 2004, 8:00am-12:00pm
Presenter: James P. Stevenson, MD
Abstract ID: 7145
Poster Number: W11
Session: Lung Cancer
Saturday, June 05, 2004, 8:00am-12:00pm
Location: Hall A (right half)<<
Cheers, Tuck |
